Last update:

Oncology & Cancer news

Oncology & Cancer

DAPK3 emerges as a new regulator of migration of triple-negative breast cancer cells

Triple-negative breast cancer (TNBC) is the subtype of breast cancer that is the hardest to treat. TNBC patients account for more than 20,000 cases of this condition annually in the U.S. alone. They experience worse outcomes ...

Oncology & Cancer

New technique that makes competition between tumor cells visible can help personalize treatments for multiple myeloma

Not all cells within the same cancer are the same. They all have genetic errors that turn them into tumor cells, but these errors are not identical. In each cancer, there are populations of cells with different mutations, ...

Oncology & Cancer

Cell line models identify cause of melanoma with drug resistance

Melanoma is a type of cancer that originates from melanocytes, the cells responsible for producing skin pigment, and is known as the most lethal form of skin cancer due to its high rates of metastasis and recurrence. With ...

Oncology & Cancer

Study explores novel therapeutic treatment for glioblastoma

Glioblastoma (GBM) is the most lethal brain tumor, with a median survival rate of merely 12-16 months after diagnosis. Despite surgical, radiation and chemotherapy treatments, the two-year survival rate for GBM patients is ...

Oncology & Cancer

Scientists get closer to a better PSA test

The most common screening test for prostate cancer so often returns a false positive result that it's no longer recommended for men older than 70, and it's offered as a personal choice for younger men.

Oncology & Cancer

Q&A: Thesis on new treatment approaches for multiple myeloma

Maria Karvouni from the Center for Hematology and Regenerative Medicine (HERM) at the Department of Medicine, Huddinge (MedH) is defending her thesis: "Cellular and personalized therapies in multiple myeloma with special ...

Oncology & Cancer

Researchers share insights on the evolution of proton radiotherapy

In a review article published in The Lancet Oncology, Susu Yan, Ph.D., and Thomas Bortfeld, Ph.D., from the Biophysics Division of MGH's Department of Radiation Oncology, and co-authors describe the evolution of proton therapy ...